References
- Peragallo JH. Pediatric myasthenia gravis. Semin Pediatr Neurol. 2017;24(2):116–121. doi:10.1016/j.spen.2017.04.003
- Hamel J, Ciafaloni E. An update: myasthenia gravis and pregnancy. Neurol Clin. 2018;36(2):355–365. doi:10.1016/j.ncl.2018.01.005
- Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis -autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12(5):259–268. doi:10.1038/nrneurol.2016.44
- Lazaridis K, Tzartos SJ. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol. 2020;11:212–224. doi:10.3389/fimmu.2020.00212
- Belasco C, Carbillon L, Louaib D, Gaudelus J, Uzan M. Neonatal myasthenia gravis. Arch Pediatrie. 2000;7(3):263–266. doi:10.1016/S0929-693X(00)88742-4
- Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol. 2007;14:38–43. doi:10.1111/j.1468-1331.2006.01538.x
- Townsel C, Keller R, Johnson K, et al. Seronegative maternal ocular myasthenia gravis and delayed transient neonatal myasthenia gravis. AJP Rep. 2016;6(01):e133–e136. doi:10.1055/s-0036-1579624
- Takamori M, Motomura M, Kawaguchi N, et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology. 2004;62(10):1894–1896. doi:10.1212/01.wnl.0000125254.99397.68
- Norata D, Peri M, Giammalva GR. Immunological aspects of von Hippel-Lindau disease: a focus on neuro-oncology and myasthenia gravis. Diagnostics. 2023;13(1):144. doi:10.3390/diagnostics13010144